CJC-1295 DAC vs CJC-1295 (No DAC)
A comparison of CJC-1295 with and without the Drug Affinity Complex (DAC), covering half-life differences, GH pulse patterns, and protocol implications.
A comparison of CJC-1295 with and without the Drug Affinity Complex (DAC), covering half-life differences, GH pulse patterns, and protocol implications.
Overview
CJC-1295 with DAC (Drug Affinity Complex) and CJC-1295 without DAC are structurally similar GHRH analogs that differ primarily in how the DAC modification binds to albumin in circulation. This single structural difference results in dramatically different pharmacokinetic profiles and shapes most protocol design decisions between the two versions.
Mechanism Comparison
Both versions act as GHRH analogs at the pituitary, stimulating GH release. The DAC modification allows albumin binding that dramatically extends plasma half-life from approximately 30 minutes (without DAC) to approximately 6–8 days (with DAC). Without DAC, CJC-1295 behaves more like Sermorelin in its pulsatile GH release dynamics. With DAC, it produces a sustained, blunted GH elevation rather than discrete pulses.
Dosing and Protocol Comparison
CJC-1295 without DAC is typically used in multiple daily injections, often paired with Ipamorelin or other GHRPs to create pulsatile GH release patterns that more closely mimic natural secretion. CJC-1295 with DAC is typically dosed once or twice weekly due to its long half-life. Protocol discussions often center on whether continuous GH elevation or pulsatile GH release better serves the specific research question.
Evidence Comparison
CJC-1295 with DAC has published clinical data demonstrating sustained IGF-1 elevation and extended GH stimulation. CJC-1295 without DAC is more commonly studied in combination peptide protocols. The choice between them in published research usually reflects the study's interest in pharmacokinetic modeling versus the practical protocol goal of mimicking natural GH secretion rhythms.